FDAnews Announces -- Building a World-Class Advertising and Promotion Review Program May 7-8, 2019 Boston, MA

Wednesday, February 27, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

FDA marketing scrutiny no longer is limited to magazine and TV ads. Now the agency is poking around, checking signage in tradeshow booths ... checking in on Twitter, YouTube and Facebook ... and listening to the physicians and other healthcare professionals you've paid to speak or train.

FALLS CHURCH, Va., Feb. 27, 2019 /PRNewswire-PRWeb/ -- Building a World-Class Advertising and Promotion Review Program

**A Two-Day Interactive Workshop Presented by PhillyCooke Consulting and FDAnews** May 7-8, 2019 Boston, MA https://www.fdanews.com/advertisingpromotion

The world of drug advertising and promotion is filled with talented people, but help is still needed. Not with creating better ads and promotions but for making sure promotional activities aren't magnets for warning letters.

Come to Boston in May for two days of intense learning. Attendees will arrive back home with a bag full of tricks and tips to keep all marketing efforts squeaky-clean.

That's not just hyperbole – aside from the great agenda, the workshop binder alone is worth the tuition cost – checklists for promotion pre-approval and effective review, FDA documents, complete and unabridged ... relevant sections of Form 2253 [CFR] ... PhRMA's Principles on DTC Advertising and Principles on Interactions with Healthcare Professionals ... ... and much more!

Plus, attendees will be up to date with the latest regulatory and enforcement trends. The agenda includes:

  • Understanding Pre-Approval Communications: Don't get on the FDA's or SEC's radar screens before your product is even approved. Learn how to properly disclose information and remain in compliance.
  • How to Maximize Disease Awareness Communications: Take away valuable tips and tricks for using disease awareness communications pre- and post-approval.
  • Hurray! You're Approved: Build the most aggressive — but compliant — campaign from first day of approval to commercial launch.
  • Assuring Your Promotions Meet FDA Off-Label Standards: Successfully navigate 4 major traps that can earn a warning letter fast.
  • Itching to do More with Social Media?: Discover how to get messages out there ... without crossing the line.
  • Understanding Off-Label Communications: How will the November 2016 memo and January 2017 guidance affect your communications?

The workshop leader is Dale Cooke, principal of PhillyCooke Consulting. Mr. Cooke's practice specializes in helping FDA-regulated companies develop compliant promotional tactics and improve the promotional review. He is the author of Effective Review & Approval of Digital Promotional Tactics and is currently at work on a book about compliant social media usage for prescription product manufacturers.

And here's a bright idea: Pass this on to ad agencies or marketing consultants. Better yet, bring them along for a crash course in the stuff that's needed!

Whatever the line of endeavor — drugs, biologics, devices — if it's advertising, the FDA has its eye on it. Why risk a Form 483 or a warning letter when compliance help is so close at hand?

Webinar Details: Building a World-Class Advertising and Promotion Review Program **A Two-Day Interactive Workshop Presented by PhillyCooke Consulting and FDAnews** May 7-8, 2019 Boston, MA https://www.fdanews.com/advertisingpromotion

Tuition: Early Bird Pricing: $1,597 (available until April 9, 2019) Regular Pricing: $1,797 (after April 9, 2019) Significant team discounts are available.

Easy Ways to Register: Online: https://www.fdanews.com/advertisingpromotion By phone: 888-838-5578 or 703-538-7600

About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store